The Role of Polymorphonuclear Leukocyte Counts from Urethra, Cervix, and Vaginal Wet Mount in Diagnosis of Nongonococcal Lower Genital Tract Infection
Table 1
Unadjusted prevalence ratios (PRs) of microscopic inflammatory signs by sociodemographic, biological and behavioral characteristics, and clinical conditions.
Characteristics
n
Total n
Prev %
PMNLs>5 (Urethral smear) PR (95% CI)
p
PMNLs>10 (Urethral smear) PR (95% CI)
p
PMNLs > epit. (Vag. wet mount) PR (95% CI)
p
PMNLs>30 (cervical smear) PR (95% CI)
p
No regular partner
236
375
63%
0.89 (0.72-1.11)
0.302
0.86 (0.56-1.33)
0.502
0.93 (0.63-1.36)
0.695
0.63 (0.47-0.84)
0.002
Regular or cohabitant partner last 6
139
375
37%
1.11 (0.89-1.38)
0.336
1.16 (0.75 - 1.79)
0.502
1.09 (0.74-1.59)
0.667
1.59 (1.19-2.11)
0.001
Partner>1 last 6 months
277
367
75%
1.26 (0.94-1.67)
0.109
0.96 (0.58 - 1.57)
0.858
1.08 (0.69-1.70)
0.733
1.23 (0.85-1.78)
0.265
Condom use vaginal sex
122
358
34%
0.82 (0.64-1.04)
0.115
0.77 (0.47 - 1.24)
0.280
0.58 (0.36-0.92)
0.021
0.78 (0.56-1.10)
0.170
Condom use last time
45
363
12%
1.06 (0.77-1.46)
0.701
0.99 (0.51 - 1.94)
0.981
0.95 (0.53-1.70)
0.867
1.01 (0.65-1.58)
0.932
Symptoms of vaginal discharge
190
375
50%
0.81 (0.65-1.00)
0.059
0.79 (0.52 - 1.22)
0.293
1.56 (1.06-2.29)
0.024
1.07 (0.80-1.43)
0.630
Dysuria
75
375
20%
1.29 (1.02-1.63)
0.030
2.00 (1.30 - 3.08)
0.002
0.98 (0.62-1.57)
0.944
1.13 (0.80-1.60)
0.465
Warts
38
375
10%
1.07 (0.76-1.50)
0.681
0.13 (0.02 - 0.91)
0.040
0.55 (0.24-1.26)
0.158
1.24 (0.81-1.89)
0.313
Cervical motion tenderness
11
375
3%
1.99 (1.60-2.47)
<0.001
2.04 (0.90 - 4.59)
0.086
3.74 (2.59-5.4)
<0.001
1.71 (0.97-2.99)
0.060
Mucopurulent endocervical exudate
36
375
10%
1.34 (1.01-1.78)
0.041
1.98 (1.18 - 3.33)
0.010
3.34 (2.38-4.69)
<0.001
2.42 (1.84-3.19)
<0.001
Endocervical bleeding easily induced
73
375
19%
1.25 (0.99-1.59)
0.060
1.15 (0.69 - 1.92)
0.594
2.46 (1.72-3.51)
<0.001
1.53 (1.12-2.08)
0.006
Cervical edema
22
375
6%
1.17 (0.78-1.74)
0.428
1.25 (0.56 - 2.8)
0.581
3.67 (2.63-5.11)
<0.001
2.08 (1.46-2.95)
<0.001
Without clinical finding for cervicitis
121
375
32%
0.80 (0.63-1.03)
0.096
0.86 (0.53 - 1.38)
0.522
0.32 (0.18-0.58)
<0.001
0.81 (0.58-1.12)
0.215
Chlamydia trachomatis
39
375
10%
1.84 (1.50-2.25)
<0.001
3.27 (2.17 - 4.94)
<0.0001
1.82 (1.16-2.85)
0.009
2.00 (1.46-2.72)
<0.001
Mycoplasma genitalium
16
372
4%
1.07 (0.65-1.78)
0.767
1.39 (0.58 - 3.34)
0.461
1.37 (0.65-2.91)
0.411
1.57 (0.94-2.63)
0.082
Mycoplasma hominis
90
375
24%
1.02 (0.79-1.31)
0.853
1.29 (0.81 - 2.05)
0.277
1.04 (0.67-1.60)
0.872
0.90 (0.63-1.28)
0.561
Ureaplasma urealyticum
91
375
24%
1.04 (0.82-1.33)
0.753
1.19 (0.74 - 1.90)
0.479
1.37 (0.92-2.04)
0.118
1.35 (1.00-1.84)
0.049
Ureaplasma parvum
299
375
80%
1.34 (0.97-1.84)
0.066
1.50 (0.81 - 2.79)
0.201
1.31 (0.78-2.19)
0.303
0.85 (0.60-1.19)
0.358
Vaginal candidiasis
69
371
19%
1.10 (0.84-1.43)
0.468
1.66 (1.05 - 2.63)
0.030
1.95 (1.34-2.85)
0.001
1.21 (0.85-1.71)
0.280
pH>4.5
148
370
40%
1.00 (0.81-1.25)
0.932
0.96 (0.62 - 1.49)
0.870
1.39 (0.96-2.01)
0.085
1.25 (0.93-1.67)
0.133
Whiff pos Amine test
105
365
29%
1.03 (0.81-1.31)
0.773
1.18 (0.75 - 1.87)
0.466
1.37 (0.93-2.01)
0.113
1.04 (0.75-1.44)
0.793
Double infection CT/MG/UU
20
375
5%
1.42 (1.01-.00)
0.046
2.33 (1.3 - 4.17)
0.005
1.82 (1.03-3.22)
0.041
1.75 (1.14-2.69)
<0.001
Previous STD
174
336
52%
0.83 (0.66-1.04)
0.110
1.16 (0.74 - 1.82)
0.507
0.99 (0.67-1.47)
0.947
1.16 (0.85-1.60)
0.336
PMNL: polymorphonuclear leukocyte, Positive NAAT, and pseudohyphae in vaginal KOH wet mount. Significant values in bold.
